Independently validating a novel modification to the Single Molecule Array technology in a pilot Alzheimer’s disease cohort
Deborah O T Alawode, Syrena Fernandes, Amanda J Heslegrave, Cheuk W Kan, David Rissin, David C Duffy, Henrik Zetterberg · 2025
Read Independently validating a novel modification to the Single Molecule Array technology in a pilot Alzheimer’s disease cohort by Deborah O T Alawode, Syrena Fernandes, Amanda J Heslegrave, Cheuk W Kan, David Rissin, David C Duffy, Henrik Zetterberg (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11714010.txt.
Description
Deborah Alawode and colleagues independently validated a more sensitive blood test platform. Their 2025 pilot study modifies the Single Molecule Array technology. The upgrade claims up to a hundredfold gain in sensitivity. Independent checks matter before such claims guide research. The team tested an interleukin 17A assay on paired samples.
Serum and spinal fluid came from Alzheimer's patients and controls. Four instruments ran the same samples for comparison. The standard machine missed the protein in all spinal fluid. Modified machines found it in nearly every spinal sample. Serum detection also jumped with the upgrade. Mean levels could then be compared across groups. Ultrasensitive tests may unlock faint brain disease signals in blood.
Catalog record
| CREATOR | Deborah O T Alawode, Syrena Fernandes, Amanda J Heslegrave, Cheuk W Kan, David Rissin, David C Duffy, Henrik Zetterberg |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |